Literature DB >> 31307867

Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature.

Ahmed Babiker1, Lloyd Clarke1, Yohei Doi1, Ryan K Shields2.   

Abstract

Among 47 patients with urinary tract infections (UTIs) due to multidrug-resistant (MDR) bacteria, treatment with fosfomycin resulted in clinical cure rates of 87% and 94% at 48 hours and 14 days, respectively. Response rates did not vary across pathogens. Our retrospective, observational findings support fosfomycin treatment against MDR pathogens causing UTIs.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRE; ESBL; Fosfomycin; UTI; VRE

Mesh：

Substances：

Year:  2019        PMID： 31307867     DOI： 10.1016/j.diagmicrobio.2019.06.008

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.983


  11 in total

1.  Ex Vivo Urinary Bactericidal Activity and Urinary Pharmacodynamics of Fosfomycin after Two Repeated Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Subjects.

Authors:  E Wenzler; K M Meyer; S C Bleasdale; M Sikka; R E Mendes; K L Bunnell; M Finnemeyer; S L Rosenkranz; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Efficacy and safety of oral fosfomycin for asymptomatic bacteriuria in kidney transplant recipients: Results from a Spanish multicenter cohort.

Authors:  María Ruiz-Ruigómez; Mario Fernández-Ruiz; José Tiago Silva; Elisa Vidal; Julia Origüen; Antonia Calvo-Cano; Enrique Luna-Huerta; Esperanza Merino; Domingo Hernández; Cristina Jironda-Gallegos; Rosa Escudero-Sánchez; Francesca Gioia; Antonio Moreno; Cristina Roca; Elisa Cordero; Darío Janeiro; Beatriz Sánchez-Sobrino; María Milagro Montero; Dolores Redondo; Francisco Javier Candel; Isabel Pérez-Flores; Carlos Armiñanzas; Claudia González-Rico; María Carmen Fariñas; Emilio Rodrigo; Belén Loeches; María O López-Oliva; Miguel Montejo; Ricardo Lauzurica; Juan Pablo Horcajada; Julio Pascual; Amado Andrés; José María Aguado; Francisco López-Medrano
Journal:  Antimicrob Agents Chemother       Date:  2021-02-08       Impact factor: 5.191

3.  Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical Pseudomonas aeruginosa Isolates.

Authors:  Elizabeth C Smith; Hunter V Brigman; Jadyn C Anderson; Christopher L Emery; Tiffany E Bias; Phillip J Bergen; Cornelia B Landersdorfer; Elizabeth B Hirsch
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

4.  Characterization of FosL1, a Plasmid-Encoded Fosfomycin Resistance Protein Identified in Escherichia coli.

Authors:  Nicolas Kieffer; Laurent Poirel; Marie-Christine Descombes; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

5.  Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000-2017.

Authors:  Ahmed Babiker; Lloyd G Clarke; Melissa Saul; Julie A Gealey; Cornelius J Clancy; M Hong Nguyen; Ryan K Shields
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

6.  In Vitro Susceptibility of Multi-Drug Resistant Klebsiellapneumoniae Strains Causing Nosocomial Infections to Fosfomycin. A Comparison of Determination Methods.

Authors:  Beata Mączyńska; Justyna Paleczny; Monika Oleksy-Wawrzyniak; Irena Choroszy-Król; Marzenna Bartoszewicz
Journal:  Pathogens       Date:  2021-04-23

Review 7.  Carbapenem-Sparing Strategies for ESBL Producers: When and How.

Authors:  Ilias Karaiskos; Helen Giamarellou
Journal:  Antibiotics (Basel)       Date:  2020-02-05

Review 8.  How to manage KPC infections.

Authors:  Matteo Bassetti; Maddalena Peghin
Journal:  Ther Adv Infect Dis       Date:  2020-05-14

9.  Distribution of Extended-Spectrum β-Lactamase Genes and Antimicrobial Susceptibility among Residents in Geriatric Long-Term Care Facilities in Japan.

Authors:  Dai Akine; Teppei Sasahara; Kotaro Kiga; Ryusuke Ae; Koki Kosami; Akio Yoshimura; Yoshinari Kubota; Kazumasa Sasaki; Yumiko Kimura; Masanori Ogawa; Shinya Watanabe; Yuji Morisawa; Longzhu Cui
Journal:  Antibiotics (Basel)       Date:  2021-12-29

10.  Clinical impact of multidrug-resistant bacteria in older hospitalized patients with community-acquired urinary tract infection.

Authors:  Manuel Madrazo; Ana Esparcia; Ian López-Cruz; Juan Alberola; Laura Piles; Alba Viana; José María Eiros; Arturo Artero
Journal:  BMC Infect Dis       Date:  2021-12-07       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.